Market Overview

Morgan Stanley Speculates On Potential Abbott Laboratories Transaction

Share:
Related ABT
Stocks Hitting 52-Week Highs
Earnings Scheduled For July 22, 2015
Abbott buys heart valve maker for $250M (Seeking Alpha)

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT).

In the report, Morgan Stanley noted, “Abbott is a unique healthcare asset, with high exposure to emerging markets and consumer- directed businesses, driving the potential for sustainable double digit earnings growth. Leverage opportunities are highly visible in both Nutritionals and Diagnostics, where peer margins demonstrate the potential for improvement. Expectations are low for the established pharma business, which has come under pressure in the developed markets and presents the potential for reacceleration as emerging market mix grows over time and austerity measures are lapped.”

Abbott Laboratories closed on Friday at $38.56.

Latest Ratings for ABT

DateFirmActionFromTo
Jul 2015BarclaysMaintainsEqual-weight
Jul 2015BMO CapitalMaintainsOutperform
Jul 2015Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

Get Benzinga's Newsletters